VCAM-1

VCAM-1 Overview

English NameVascular cell adhesion molecule 1Approved Drugs2
Drugs in Clinical Trials1Target SynonymVCAM1,Vascular cell adhesion protein 1,V-CAM 1,CD106,Vascular Cell Adhesion Molecule 1,CD106 Antigen,INCAM-100,VCAM-1,Vascular Cell Adhesion Molecule-1
Highest Development StageApproved
English NameVascular cell adhesion molecule 1
Target SynonymVCAM1,Vascular cell adhesion protein 1,V-CAM 1,CD106,Vascular Cell Adhesion Molecule 1,CD106 Antigen,INCAM-100,VCAM-1,Vascular Cell Adhesion Molecule-1
Approved Drugs2
Drugs in Clinical Trials1
Highest Development StageApproved

VCAM-1 Background

Vascular cell adhesion protein 1 (VCAM1) is also known as CD106, INCAM-100 and L1CAM, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. VCAM1 / CD106 contains 7 Ig-like C2-type (immunoglobulin-like) domains. CD106 / VCAM-1 is expressed on inflammed vascular endothelium, as well as on macrophage-like and dendritic cell types in both normal and inflammed tissue. L1CAM / VCAM-1 is Important in cell-cell recognition and appears to function in leukocyte-endothelial cell adhesion. CD106 / VCAM1 interacts with the beta-1 integrin VLA4 on leukocytes, and mediates both adhesion and signal transduction. The VCAM1 / VLA4 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. INCAM-100 / VCAM1 binds to ECMV-D capsid proteins and acts as a receptor for this virus.

VCAM-1 Synonyms

VCAM1,CD106,INCAM-100,V-CAM 1,VCAM-1

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
99mTc-cAbVCAM1-599mTccAbVCAM1‐5; 99mTc-cAbVCAM1-5Phase 1 ClinicalMedico-Economic Evaluation Unit , University Hospital, GrenobleAtherosclerosis; Cardiovascular Diseases
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Tocopherol acetateDSE-9912ApprovedNational Institute Of Diabetes And Digestive And Kidney DiseasesEphynal, Aquasol EJapanVitamin E Deficiency; Diabetic Retinopathy; Atherosclerosis; Intermittent Claudication; Venous Thromboembolism; ThrombosisEisai Co Ltd1951-09-01Atherosclerosis; Diabetic Retinopathy; Intermittent Claudication; Metabolic Dysfunction-Associated Steatotic Liver Disease; Thrombosis; Venous Thromboembolism; Vitamin E Deficiency
Details
Ascorbic Acid/Biotin/Cholecalciferol/Cyanocobalamin/Dexpanthenol/Folic acid/Niacinamide/Pyridoxine/Riboflavin/Thiamine/Tocopherol Acetate/Vitamin A/Vitamin KApprovedSandoz Canada IncInfuvite PediatricUnited StatesAvitaminosisSandoz Canada Inc2001-02-21Avitaminosis
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information